Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIiwWYcx6oDVMUCwNEDPxG1? MV[yOEBpyqB? NVPmdWN{cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NFjxe2MzPjB6OEexNS=>
POLK WT NFPpPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvmU4duUUN3ME2xNU446oDLwsJihKkyNjgEoN88US=> NVHFSodlOjZyM{G0NFA>
POLK KO M{npZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\1TWM2OD12LkCz5qCKyrIkgJmxMlkzyqEQvF2= NEfLV4EzPjB|MUSwNC=>
POLK CD Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXrTWM2OD13LkW55qCKyrIkgJmxMlAxyqEQvF2= Ml60NlYxOzF2MEC=
RLE/Abca3 MUDGeY5kfGmxbjDBd5NigQ>? MYOwMlTDqM7:TR?= NH\yfZYyPDUEoHi= MlT4bY5lfWOnczDhJI1wenCqb3zv[4lk[WxiY3jhcodmKG[{b32g[ZBqfGinbHnhcE1tcWunIH3vdpBpd2yxZ4mgeI8h[SC5aXTlMEB{eHKnYXStc5V1KG2xcoDoc4xw\3oEoB?= NF\jc2YzPTd4MEWzPC=>
PMCs MYTGeY5kfGmxbjDBd5NigQ>? M3Xme|AvOeLCk{NCpO69\y:vbB?= NYD5[Vc1OjUEoHi= MorGZ4F2e2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKHC{b4TlbY4hdGW4ZXygc4Yh[2:ubHHn[Y4uUcLi NIX3OmgzPTV7NU[0Ni=>
PMCs Ml34SpVv[3Srb36gRZN{[Xl? MWewMlLDqM7:Zz;tcC=> NX;ZNlgzOjUkgKO3NuKhcA>? NGHpVmRqdmS3Y3XzJIlv[3KnYYPld{BqdiC4aX3lcpRqdiCjbnSg{tEuW02DIIDyc5RmcW5? MYiyOVU6PTZ2Mh?=
PMCs NXL6[W5STnWwY4Tpc44hSXO|YYm= NEf5UYYxNjMEoN88[{9udA>? NXTs[HEzPzJiaB?= MYHpcoR2[2W|IHTlZ5Jm[XOnczDpckBkgXSxa3XyZZRqdi16IHHu[EBGNWOjZHjldolvKHC{b4TlbY4> MoLNNlU2QTV4NEK=
PMCs NX60d2M1TnWwY4Tpc44hSXO|YYm= NETsfY4xNjMEoN88[{9udA>? MVixNk8zPC92ODDo M4P1Wolv[3KnYYPld{Bk\WyuIH3p[5JifGmxbh?= MYiyOVU6PTZ2Mh?=
IMR-32 Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnYUWtCPy534pkSNVIxKML3Zz;tcC=> MXKxNwKJmjR6IHi= NVX3dpBTUUN3ME22NEDDvWdxbXygZZQhfGinIHXu[EBw\iB{NDDodpMhd2ZiaX7jeYJifGmxbh?= M1f3[FI2PTN4M{S1
HT1080 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGxJO69VQ>? M3Lae|I1KGkEoB?= NULGV3FvdGWjZIOgeI8h[SCJMj;NJIRmdGG7 NUjEe48{OjV3MUi5OlE>
HT1080 NY\VWGVwTnWwY4Tpc44hSXO|YYm= NIq3U|cyKM7:TR?= MWmyOEBpyqB? Ml3XbY5lfWOnczDhJJBwfGWwdDDncI9j[WxiRF7BJIRidWGpZTDy[ZNxd26|ZR?= MlfoNlU2OTh7NkG=
HDFn NXP1WmxCS3m2b4TvfIlkcXS7IFHzd4F6 NFGzSVg4OiCq NVTWcVNQUUN3ME25MlMyLcLi M{LSVlI2Ojd4N{my
THP-1 M2DL[mN6fG:2b4jpZ4l1gSCDc4PhfS=> NXvHTHN6PzJiaB?= NITFd|dKSzVyPUSuO|cm MWCyOVI4Pjd7Mh?=
HT-29 NYTpbGlPS3m2b4TvfIlkcXS7IFHzd4F6 NXvGXIE3PzJiaB?= NW\6eJN3UUN3ME2xNU41QSV? M4\ZdVI2Ojd4N{my
HCT116  MoXJR5l1d3SxeHnjbZR6KEG|c3H5 MYe3NkBp NWfIe3FmUUN3ME2xNU4{PCV? MnXBNlUzPzZ5OUK=
A431 M1POemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXPVI5EPTBvMkCwJGlW NXfrPVh1PDkkgJno MWLpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MmLtNlUyODF{OUm=
T24 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nFfFUxNTJyMDDJWS=> MXu0PQKBkWh? NGDlT5JqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MUWyOVExOTJ7OR?=
AY-27  MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm1NE0zODBiSWW= NHrvOnE1QOLCiXi= MlH4bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M1H4eFI2OTBzMkm5
A549 NVjHbFYyTnWwY4Tpc44hSXO|YYm= MYWxJOK2\y:vTNMg NHXTWZAxNTR6IHi= MnLEbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> NHHZbHMzPDl4M{[zOS=>
MLE12 M174SGZ2dmO2aX;uJGF{e2G7 NYeySVJNOSEEtXevcWzDqA>? NVHSR|FTOC12ODDo MYDpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> NWnr[ml2OjR7NkO2N|U>
Jurkat NF\PZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\wSFIx6oDLzszt NVj6d2ZJOjUkgJnoxsA> NYLkZoVW[XK{ZYP0d{B1cGViY3XscEBkgWOuZTDheEB1cGViR{KgdIhie2V? NHfGVmgzPDlzNki5Ny=>
HeLa  NF\LS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFyLkNCpO69VQ>? M1T6[VI1PzN{M{m3
C18-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojCNE0yODBizszN NYSydYpVcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M17xflI1PTdzOUiy
BMG-1  Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS0NE85OMLizsznM40> MoW3N:KhcA>? MnWxbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mnn6NlM6ODZ5Mk[=
A459 MVLBdI9xfG:|aYOgRZN{[Xl? MYCxNEBuXQ>? NH3YZXQ1QCCq NYrsUJE3cW6mdXPld{BieG:ydH;zbZM> NFSzT2ozOzlyMke2Oi=>
MOCK MlnBRZBweHSxc3nzJGF{e2G7 NY\wXZpuOTBibWW= M{SyV|Q5KGh? NIrTclBqdmS3Y3XzJIFxd3C2b4Ppdy=> NWnleVJ3OjN7MEK3OlY>
MMP1 MoTORZBweHSxc3nzJGF{e2G7 MmDONVAhdVV? NFW0OJI1QCCq NFyzToFqdmS3Y3XzJIFxd3C2b4Ppdy=> MXmyN|kxOjd4Nh?=
A549 NWDZXZhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG3VY8zODBizszN M3PUe|I1KGkEoB?= NXjs[o0{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NGXYSo8zOzhyNUe5Ny=>
HCT-116 M17N[GFxd3C2b4Ppd{BCe3OjeR?= M{XWfFMwPy53L{G1JO69\y:vbB?= NXnpbZFNPDhiaB?= NVjl[ZdJemWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? M1\uV|I{PzB6Nk[4
HeLa MVfBdI9xfG:|aYOgRZN{[Xl? Mme1N{84NjVxMUWg{txoN22u Mli4OFghcA>? NYPtU|VYemWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? NVXBfGFMOjN5MEi2Olg>
HCT116 NWDIOolbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUewMVExOCEQvHevcYw> NHS2dlI1QCCq MYHpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 Mmr2NlM2OTh{MEG=
NCM460 M3vtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\DeVAuOTByIN88[{9udA>? MkT1OFghcA>? NYHzOXV[cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MlXMNlM2OTh{MEG=
NT2  NEOzRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfMZpozPCCqwrC= NV;4Z2EzVER3ME20NFDjiIoEtXevcYw> M1m2PVI{Ozh4NEKw
NT2  MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYK0PEBp NEnkflFNTDVyPUGwNEDDvWdxbXy= NHvINoEzOzN6NkSyNC=>
NT2  Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjqVpI4OiCq NF;uXJBNTDVyPUKw5qCKyrWpL33s MV6yN|M5PjR{MB?=
NT2  NXvne4xRSXCxcITvd4l{KEG|c3H5 NFTJdmg1ODEkgJpCuYcwdWx? NEPufnMzPCCqwrC= MWjpcoR2[2W|IIPp[45q\mmlYX70JIlv[3KnYYPld{BqdiClYYPwZZNmNTNuODy5JIFkfGm4aYT5xsA> NEC1RpAzOzN6NkSyNC=>
NTera-2 MoXvSpVv[3Srb36gRZN{[Xl? MlTiNVIxKM7:Zz;tcC=> MVe3NkBp MULzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyB6LXnzc5Bzd3O2YX7lJIxmfmWucx?= M{nNTlIzQDJ3M{W1
NCCIT M13GWmZ2dmO2aX;uJGF{e2G7 MXqxNlAh|rypL33s NGnFfYQ4OiCq NWjRWngxe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> M4L1RVIzQDJ3M{W1
NTera-2 MYnGeY5kfGmxbjDBd5NigQ>? NGP1blQyOjBizsznM41t NYDnO5Z7PzJiaB?= M{HzW5Nq\26rZnnjZY51dHliaX7jdoVie2W|IGTCRXJUKGyndnXsdy=> NV\o[m5FOjJ6MkWzOVU>
NCCIT MVXGeY5kfGmxbjDBd5NigQ>? NYTWU3NTOTJyIN88[{9udA>? M1rHWFczKGh? NUK5NWxQe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ NHLKeXEzOjh{NUO1OS=>
NCCIT NIPiV3hHfW6ldHnvckBCe3OjeR?= NWqwcmdxOTJyIN88[{9udA>? NFvFRWw4OiCq NUDm[WUze2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgS3NJKGyndnXsdy=> NFPtd4szOjh{NUO1OS=>
NTera-2 NEG0OW1HfW6ldHnvckBCe3OjeR?= MmG3NVIxKM7:Zz;tcC=> MX:3NkBp NUHtdmVue2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgVJJwfGWrbjDjZZJjd267bDDs[ZZmdHN? NYD5d4ZVOjJ6MkWzOVU>
NCCIT NWTSU3p2TnWwY4Tpc44hSXO|YYm= NVXz[|YzOTJyIN88[{9udA>? NIr4eIE4OiCq MnHVd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> M1uxU|IzQDJ3M{W1
NTera-2 MofPSpVv[3Srb36gRZN{[Xl? NWXaS3VoOTJyIN88[{9udA>? NHLYXIg4OiCq NYe5WIo1e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> NYjCc2hTOjJ6MkWzOVU>
NCCIT NY\nfG9TTnWwY4Tpc44hSXO|YYm= Mm[yNVIxKM7:Zz;tcC=> MonHO|IhcA>? NHewTVZ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz MVmyNlgzPTN3NR?=
MDA-MB-468 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfjPVUx6oDVMkCwxsDPxGdxbVy= NIXjNGEzPCCq M3vxeolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NUXmS5RIOjJ6MUmxPVY>
231-H2N M3jjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSw5qCUOjBywrFOwIcwdUx? MkLtNlQhcA>? NXvsdndbcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NGXVT2MzOjhzOUG5Oi=>
A549  M3zJbWZ2dmO2aX;uJGF{e2G7 NWfVcHE4OjByL{SwNEDPxE1? NVjlOFh4emW|dXz0d{BqdiCjIHTvd4UuemW|cH;ud4l3\SCrbnPy[YF{\SCrbjDSU3M> MlzwNlI4PzN4OUe=
A549  NHfRSoVHfW6ldHnvckBCe3OjeR?= M3HFWlAuPDByIN88US=> NHjpNogzNTR6IHi= MUHjZZV{\XNibX;y[UBufESQQTD0bIFvKG6GTlGg[IFu[Wen M4POVFIzPzd|Nkm3
A549  NX3CdY15TnWwY4Tpc44hSXO|YYm= MlyzNVAxKM7:TdMg MnPVNQKBmzR6IHi= M2TCVYNifXOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> MoTzNlI4PzN4OUe=
A549  NILmTpFHfW6ldHnvckBCe3OjeR?= Ml30NVAxKM7:TdMg MlX3NQKBmzR6IHi= NXGy[IFL[2G3c3XzJHBMTDFiY3zlZZZi\2V? MYCyNlc4OzZ7Nx?=
A549  NUXrOG5DTnWwY4Tpc44hSXO|YYm= MnTNNVAxKM7:TdMg MYSw5qCUPDhiaB?= MkPJZ4F2e2W|IH3peI9kcG:wZILpZYwhdG:lYXzpfoF1cW:wIH;mJGJigA>? NVHJO|RQOjJ5N{O2PVc>
A549  MnfqSpVv[3Srb36gRZN{[Xl? NVHJZoIzOTByIN88UeKh NFn1SHMx6oDVNEigbC=> NUjtWHFL\GWlcnXhd4V{KE2PUDDhcoQhSVSSIHzleoVtew>? NX;SeYZ7OjJ5N{O2PVc>
MCF-7/Her-18  MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW3c|ZoOC52Mj2xO|AxKM7:Zz;tUC=> M2rsS|I1KGh? M{fNS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NUHDZ5BYOjJ4MkG0NFQ>
MCF-7 NIKzXWFRTFRxUFPJJHRz\WG2bXXueC=> MYKwMlI2KM7:Zz;tcE4> NVHFN5k2OS12IHi= MnfYd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> MkDPNlI2QTF{OES=
MDA-MB-231 MlfvVGRVN1CFSTDUdoVifG2nboS= NYPFenQ3OC5{NTFOwIcwdWxw MYSxMVQhcA>? MV3zbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 NYPONpA5OjJ3OUGyPFQ>
MDA-MB-235  MYTQSHQwWEOLIGTy[YF1dWWwdB?= NHHubYQxNjJ3IN88[{9udC5? NV3CPZE3OS12IHi= MlTtd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> M{TiclIzPTlzMki0
MCF-7 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDPbHgxNTJizsznM41tNg>? M2n1e|I1NzR6IHi= MnzxSWM2OD1zLkKg{txoN22O MkfZNlI2QTF{OES=
NCCIT  NV\ycoJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf6NFRuOjEkgKOxOFDDqM7:Zz;tcC=> M4\6[VczKGh? MkSxUGQ2OD1zMkFCpO69\y:vbNMg MWqyNlU3OjF4MB?=
NCCIT  NVrUboh{TnWwY4Tpc44hSXO|YYm= M4[welczKGh? MofNd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= NIfHPJEzOjV4MkG2NC=>
NCCIT  Ml7KSpVv[3Srb36gRZN{[Xl? NWToSJVrPzJiaB?= Mn71d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S16IHHjeIl3cXS7wrC= NWP1cYdzOjJ3NkKxOlA>
NCCIT  NHi4PYhHfW6ldHnvckBCe3OjeR?= NVvkTHZqPzJiaB?= MVrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTliYXP0bZZqfHoEoB?= NYrTdGd7OjJ3NkKxOlA>
NCCIT  M3rNTmZ2dmO2aX;uJGF{e2G7 MU[3NkBp MUHzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? MUiyNlU3OjF4MB?=
NCCIT  MVjGeY5kfGmxbjDBd5NigQ>? NIXZS2U4OiCq NX;EWXlqe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKEKlbD2yJINwdnSnboS= NFvXToQzOjV4MkG2NC=>
NCCIT  NEDsTFlHfW6ldHnvckBCe3OjeR?= NHfKS444OiCq NVTtT3pye2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKEO7dD3jJIxmfmWu MVWyNlU3OjF4MB?=
HeLa NHrBdo1HfW6ldHnvckBCe3OjeR?= NGLsSpE{OC95MDFOwIcwdWx? NF7qfFgzPMLiaB?= MnvzbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKheDV|78{MRXRONHB{MdMgZY5lyqCJQVTEOFU> MVqyNlQ5Pzl|Nx?=
MCF-7  NYPE[4N5TnWwY4Tpc44hSXO|YYm= MknJN|AwPzBizsznM41t M2rrUVI1yqCq NX3JSmlWcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLicEWz89yNSVSPLICyNeKh[W6mwrDHRWRFPDV? MlPxNlI1QDd7M{e=
HeLa NV3jW3RnS3m2b4TvfIlkcXS7IFHzd4F6 MkLGN|AwPzBizsznM41t NF\EdmMzPMLiaB?= NUf0WXdNcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt M3y3OFIzPDh5OUO3
MCF-7  MkjZR5l1d3SxeHnjbZR6KEG|c3H5 NVTpfHFKOzBxN{Cg{txoN22u M{\ZfVI1yqCq NGrl[2lqdmS3Y3XzJIhq\2iueTDzbYdvcW[rY3HueEBt\X[nbIOgc4Yh\nKjZ33lcpRm\CCGTlGgdoVt\WG|ZTDpcpRwKHSqZTDjfZRweGyjc32= NHn4OoIzOjR6N{mzOy=>
NT2 NV\ybHY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPFNVAxNTZyMNMg{txoN22u M3\jTVI1KGh? Mny1TWM2OD12MECgxtVoN22u MXqyNlQ3QTl3Mh?=
NT2 NH61ZVhHfW6ldHnvckBCe3OjeR?= MUK0NFDDqM7:Zz;tcC=> MXKyOEBp Mk\xd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|LEisPUBi[3Srdnn0feKh M{PXTFIzPDZ7OUWy
NT2 MV3GeY5kfGmxbjDBd5NigQ>? Mn;qOFAxyqEQvHevcYw> NYO2b4ZHOjRiaB?= MWPzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NV3XPJk2OjJ2Nkm5OVI>
NT2 MoWzSpVv[3Srb36gRZN{[Xl? MYq0NFDDqM7:Zz;tcC=> NYS1R3BmOjRiaB?= M2PZV5Nq\26rZnnjZY51dHliZHXjdoVie2W|IFLjcE0zKGyndnXs M{DaWFIzPDZ7OUWy
CHO Ml3VSpVv[3Srb36gRZN{[Xl? MojTNk42yqEQvHevcYw> Mnu5NVghcC94IHS= Mn:xbY5lfWOnc9MgdIVze2m|dHXuZ4Uhd2ZiY3jyc41we2:vZTDkZY1i\2V? NW\tdllOOjJ{M{CxPVU>
Jurkat MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXlWZExNTFyMNMg{txoN22u NF\ocIkzPCCq NUW0Rllv[XK{ZYP0d{B1cGViY3XscEBkgWOuZTDheEB1cGViR{KgdIhie2V? NV;4NoJwOjJ{MkOzN|I>
Jurkat Mn3YSpVv[3Srb36gRZN{[Xl? M1jmd|MxyqEQvHevcYw> M4HUelI1KGh? MX;pcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKGO7Y3zpcpMhTDNuIFGgZY5lKEJz NXnkeoVxOjJ{MkOzN|I>
Jurkat MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf3NE0yODEEoN88[{9udA>? M1XDXVI1KGh? NHHBOVNqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDhckBKSzVyII\hcJVmKG:oIEGwNO69\y:vTB?= NVPaW2w5OjJ{MkOzN|I>
Jurkat NXHSOoVbTnWwY4Tpc44hSXO|YYm= MX6zNOKh|rypL33s NUS2cGZCOjRiaB?= NGnmUmVqdmO{ZXHz[ZMhfGinIHXm[oVkfCCxZjDwfYNvcWSrb37lJI9vKHCqb4PwbI9zgWyjdHnvckBt\X[nbIOgc4YhcGm|dH;u[UBJOkFwWB?= M4G3R|IzOjJ|M{Oy
U2OS EGFPnls MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGwMVLDqM7:Zz;tcC=> NX7QNmp4OjRiaB?= NIXkWVhqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M4O4VlIyQDFzMEC3
U2OS KuEnls MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\zNE0zyqEQvHevcYw> M4H5eVI1KGh? MWjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MVSyNVgyOTByNx?=
MCF-7 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXVNE01ODBizszN M2\ZPFczKGh? MmXoUGM2OD1zNUGuPOKh|ryP NF:zeoEzOTdyM{K5NS=>
MCF-7/Adr  NEHV[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf6PGZYOC12MECg{txO MX:3NkBp M4\sT2xEPTB;NUiuOeKh|ryPwrC= M{\KVFIyPzB|Mkmx
WI-38 MoLBSpVv[3Srb36gRZN{[Xl? NFTmcYgxNzRyL{iw5qCK|rypL33sxsA> MUizJIg> NYHOOWVycW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? M1TRc|IyPTl7NkGy
hBMSC MmnNSpVv[3Srb36gRZN{[Xl? NEPs[osxNzRyL{iw5qCK|rypL33sxsA> MXqzJIg> M2H4W4lv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> MmDONlE2QTl4MUK=
NCI-H23 NETvcJNHfW6ldHnvckBCe3OjeR?= MoLYNE81OC96MPMAje69\y:vbNMg NHPxe5Q{KGh? MX3pcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg NYDxRnpNOjF3OUm2NVI>
A-549 NXTqRZd5TnWwY4Tpc44hSXO|YYm= M{jo[lAwPDBxOEFihKnPxGdxbX|CpC=> NEHuXWk{KGh? M4fyOolv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NEWyRWQzOTV7OU[xNi=>
PBL  NX61[JBkTnWwY4Tpc44hSXO|YYm= NXToVY9yOC92MD:4NQKBkc7:Zz;tcOKh M1r6bFMhcA>? MUjpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg MmTXNlE2QTl4MUK=
pol β −/− MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTD[nAxNjJ3LUKwNOKh|rypL33s MYCyOOKhcA>? Mlmy[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh MYqyNVI2OTl2NB?=
pol β +/+ MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf3cYsxNjJ3LUKwNOKh|rypL33s MUiyOOKhcA>? NInweJRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? NYD4ZXRPOjF{NUG5OFQ>
pol β −/− M{j0PGZ2dmO2aX;uJGF{e2G7 MWiwMVIvPSEQvHevcYw> M{fpdFIhcA>? NF\0XJVk[XW|ZYOgSG5CKGSjbXHn[S=> NU[xfotOOjF{NUG5OFQ>
pol β +/+ Ml7QSpVv[3Srb36gRZN{[Xl? NYjjUnJ3OC1{LkWg{txoN22u MW[yJIg> MoTtZ4F2e2W|IFTORUBl[W2jZ3W= MkLhNlEzPTF7NES=
pol β −/− M2Ozc2Z2dmO2aX;uJGF{e2G7 MWqwMVUh|rypL33s MkLSOFghcA>? NWrnSnhF[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MXeyNVI2OTl2NB?=
pol β +/+ NGjUNYNHfW6ldHnvckBCe3OjeR?= NG\1enQxNTVizsznM41t MkHPOFghcA>? NYXYXWxj[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NYPOcpVSOjF{NUG5OFQ>
TK6  MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm3NlUuOTVyIN88[{9udA>? NX\VXFhjQTZiaB?= M1jxeolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NYnMbVVHOjFyOEG0PFc>
TK6  sLUC+Apn1 M{TSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LWUlI2NTF3MDFOwIcwdWx? Mme1PVYhcA>? NHz6[4xqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MV[yNVA5OTR6Nx?=
TK6 sAPE1+Apn1 Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\melI2NTF3MDFOwIcwdWx? MlnNPVYhcA>? NVfYe2xte2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NXPjOWRkOjFyOEG0PFc>
HCT116 M2rGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3wVZptOjVvMUWwJO69\y:vbB?= MlXCPVYhcA>? NVe1VItEcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M{DtSFIyODhzNEi3
HCT116 sLUC+Apn1 M{f6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLzWZgzPS1zNUCg{txoN22u MUG5OkBp MYPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MoDkNlExQDF2OEe=
HCT116 sAPE1+Apn1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XVTFI2NTF3MDFOwIcwdWx? M2TGflk3KGh? M2fLW5Nq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= NWfZeXVoOjFyOEG0PFc>

... Click to View More Cell Line Experimental Data

In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How about the strength of Bleomycin Sulfate(S1214) in terms of Units/mg?

  • Answer:

    Our S1214 Bleomycin Sulfate is 1500 Units/mg.

  • Question 2:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

Related Antibodies

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID